Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst & Investor Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am...

from PR Newswire: https://ift.tt/2PsAm6I